12.01
+0.22(+1.87%)
Currency In USD
| Previous Close | 11.79 |
| Open | 11.96 |
| Day High | 12.28 |
| Day Low | 11.85 |
| 52-Week High | 15.74 |
| 52-Week Low | 2.32 |
| Volume | 403,985 |
| Average Volume | 1.29M |
| Market Cap | 649.88M |
| PE | -10.54 |
| EPS | -1.14 |
| Moving Average 50 Days | 10.19 |
| Moving Average 200 Days | 7.17 |
| Change | 0.22 |
If you invested $1000 in Fulcrum Therapeutics, Inc. (FULC) since IPO date, it would be worth $889.63 as of December 25, 2025 at a share price of $12.01. Whereas If you bought $1000 worth of Fulcrum Therapeutics, Inc. (FULC) shares 5 years ago, it would be worth $941.96 as of December 25, 2025 at a share price of $12.01.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Dec 10, 2025 12:48 PM GMT
CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
GlobeNewswire Inc.
Dec 08, 2025 9:01 PM GMT
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined r
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
GlobeNewswire Inc.
Dec 06, 2025 10:30 PM GMT
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week 6 (vs. 5.6% at Week 6 in the 12 mg cohort); 7 of